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Abstract
Introduction
• Elective total knee arthroplasty (TKA) is the most frequently performed 
inpatient surgical procedure in the United States, with an estimated 700,000 
TKAs performed in 2010 and a projected 3.48 million procedures per year 
by 2030 (Kurtz, Ong, Lau, Mowat, & Halpern, 2007). Well-known 
complications of this procedure include DVT and PE, collectively referred 
to as VTE. Without utilization of prophylactic measures, the reported risk of 
venographically documented DVT in patients undergoing TKA ranges from 
41-85%. Since the implementation of VTE prophylaxis, a reduction in VTE 
events of 0.6-1% during hospitalization and 2-3% at three months 
postoperatively has been reported (Kakkar & Rushton-Smith, 2013). 
Various pharmacological agents exist for the purpose of VTE prophylaxis. 
Such agents include aspirin, clopidogrel, warfarin, LMWH, and novel 
anticoagulants including factor Xa inhibitors and DTIs. The American 
College of Chest Physicians (ACCP) and the American Academy of 
Orthopedic Surgeons (AAOS) initially had differing views regarding the 
superior VTE prophylaxis regimen for patients undergoing major orthopedic 
surgery, which includes TKA. However, as of 2012, the ACCP and AAOS 
have both approved of the sole use of aspirin as a means of VTE 
prophylaxis (Stewart & Freshour, 2013). The ACCP recommends use of 
LMWH, fondaparinux, dabigatran, apixaban, rivaroxaban, low-dose 
unfractionated heparin (UFH), vitamin K antagonists, or aspirin for a 
minimum of ten to fourteen days postoperatively (Falck-Ytter et al., 2012). 
The AAOS recommends using prophylaxis but does not currently endorse a 
single, superior medication (AAOS, 2011).  
Research Question
Literature Review




• Among the current pharmacologic options for VTE prophylaxis 
following TKA, does a superior drug or combination of drugs exist 
based on patient outcomes? 
– Multiple medication options exist for postoperative DVT prophylaxis 
following TKA.  
– Each option possesses a unique mechanism of action and side effect 
profile; further, variable efficacy and associated cost must be considered 
in analyzing the utility of each option in each patient case. 
– Among the agents, aspirin and factor Xa inhibitors have demonstrated the 
most growth in utilization for DVT prophylaxis following TKA; they 
have demonstrated adequate efficacy as well. Factor Xa inhibitors are 
associated with an increased cost and risk of bleeding, but they also 
exhibit a slightly decreased risk of VTE compared to aspirin.
– Aspirin demonstrates comparable outcomes, with only a slightly 
increased risk of VTE as noted above and are available for a fraction of 
the cost of factor Xa inhibitors. Warfarin continues to be the drug of 
choice in patients with mechanical heart valves requiring 
chemoprophylaxis. 
• Which of the current pharmacologic VTE prophylaxis options 
demonstrates the greatest cost effectiveness with the fewest risks? 
– Medication cost incurred by the patient is difficult to determine due to 
varying insurance coverage and out of pocket expenses. A website 
(www.goodrx.com) was utilized to obtain average cost of each 
medication. The following costs do not include any insurance coverage. 
The cost of 365 aspirin (81 mg tablets) was $5.70. The cost of 60 
apixaban (5 mg tablets) was $454. The cost of 30 warfarin (5 mg tablets) 
was $18.25. Finally, the cost of a 30-day supply of enoxaparin (40 
mg/0.4mL syringes) was $929.65. 
– Duran et al. (2012) completed research evaluating the cost-effectiveness 
of rivaroxaban versus enoxaparin for VTE prophylaxis in patients 
undergoing THA and TKA from a United States payer's perspective. 
• Researchers utilized a decision-analytic model that was divided into 
the following three sub-modules according to the patient’s 
anticoagulation: prophylaxis, post-prophylaxis, and long-term 
complications.
• The researchers found that rivaroxaban was associated with a cost 
savings of $465.74 per patient and prevented an average of 0.0193 
symptomatic VTE events per patient. Sensitivity analysis 
demonstrated a cost savings ranging from $293.01 to $848.68.
– Mostafavi et al. (2015) examined the cost effectiveness of aspirin 
compared to warfarin in TKAs. The researchers used a Markov cohort 
cost effectiveness analysis that compared the costs, health benefits, and 
the costs per quality adjusted life year (QALY) for patients 55 to 85 years 
of age. The results of their analysis revealed aspirin was more cost 
effective than warfarin in the majority of patients undergoing TKAs. In 
patients with a high probability of VTE and a low probability of bleeding, 
however, warfarin was more cost effective
• Elective total knee arthroplasty (TKA) is the most frequently performed 
inpatient surgical procedure in the United States (Kurtz, Ong, Lau, Mowat, 
& Halpern 2007). Complications of this procedure include deep vein 
thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as 
venous thromboembolism (VTE). Various pharmacological agents exist for 
VTE prophylaxis. Warfarin and low-molecular-weight heparin (LMWH) 
were commonly used for VTE prophylaxis in the past, but with the 
emergence of novel anticoagulants including factor Xa inhibitors and direct 
thrombin inhibitors (DTIs), warfarin is used far less frequently. Aspirin is 
also approved for VTE prophylaxis. The purpose of this study was to 
determine if a superior drug or combination of drugs exist for VTE 
prophylaxis based on patient outcomes, cost effectiveness, and risk profile. 
This review of literature analyzed studies from the past 10 years that 
compared aspirin, warfarin, Lovenox, and the novel anticoagulants for VTE 
prophylaxis in post-operative TKAs. Study outcomes included VTE 
prevention, bleeding risk, and cost. Reversal agents were also examined. 
Findings of this author’s literature review demonstrated that currently, no 
one superior medication exists for prophylaxis of VTE events in patients 
undergoing TKA (Cafri et al., 2017). However, current research indicates 
that both factor Xa inhibitors and aspirin have emerged as the medications 
of choice. Of the two, aspirin is commonly favored as it does not require 
laboratory monitoring, it is cost effective, and it is available over the 
counter.  It also has less risk of major bleeding compared to factor Xa 
inhibitors. 
• Among the current pharmacologic options for VTE prophylaxis following 
TKA, does a superior drug or combination of drugs exist based on patient 
outcomes? 
• Which of the current pharmacologic VTE prophylaxis options demonstrates 
the greatest cost effectiveness with the fewest risks? 
• An online database search of PubMed, Dynamed, Cochrane, and Science Direct 
were utilized to find research articles regarding outcomes of different 
medications for VTE prophylaxis in patients undergoing TKAs.
– Pharmacology of medications included in this literature review were obtained 
from various, up to date, credible textbooks and research articles.
– Studies were included if the patient population underwent a TKA, received 
VTE prophylaxis, and did not have a prior heart valve repair or preexisting 
condition requiring prior anticoagulation therapy.
– Studies also had to be from within the last 10 years. Study participants were 
all adults. 
• In a systematic review, Vincent, V. G., Phan, K., Yadin, L., & Warwick, B. (2009) 
examined the efficacy of aspirin in preventing VTE in patients undergoing THA 
or TKA
– The overall rates of DVT and PE in the THA and TKA populations were 1.2% 
and 0.6%, respectively. The rate of major bleeding was 0.3%, and the pooled 
mortality rate was 0.2%. The researchers concluded that aspirin used both 
alone and in combination for thromboprophylaxis resulted in a low rate of 
VTE and major bleeding complications.
• Wilson, Poole, Chauhan, & Rogers, (2016) performed a systematic review of 13 
total studies investigating the efficacy of aspirin for DVT prophylaxis compared 
to warfarin, enoxaparin, factor Xa inhibitors, and direct thrombin inhibitors 
following THA and TKA. 
– Wilson et al. (2016) concluded that insufficient evidence existed to establish 
one medication as superior and that each had a unique side effect profile to be 
considered on a case-by-case basis.
• Vincent et al. (2009) performed a systematic review to determine the efficacy of 
aspirin in preventing VTE in patients undergoing a TKA or THA.
– The researchers concluded that aspirin used both alone and in combination for 
thromboprophylaxis resulted in a low rate of VTE and major bleeding 
complications. This study demonstrated aspirin can be used as a sole means of 
VTE prophylaxis in postoperative TKA patients. 
• Stewart et al. (2013) evaluated the suitability of aspirin in prevention of VTE in 
high-risk orthopedic surgery patients. After analysis, researchers were unable to 
conclude whether aspirin was a safe and effective option for VTE prophylaxis in 
high-risk patients undergoing THA, TKA, or hip fracture surgery. They 
concluded that enough validation existed for practitioners to use aspirin as the 
sole means of VTE prophylaxis, but not enough validation existed to recommend 
a change to sole use of aspirin for practitioners who currently use a more potent 
anticoagulant. 
• Neumann et al. (2012) evaluated the risks and benefits of oral direct factor Xa 
inhibitors versus LMWH in patients undergoing TKA or THA.
– The factor Xa inhibitors did show a significant reduction in symptomatic 
DVTs compared to enoxaparin. 
• Bala et al. (2017) performed a study utilizing Humana and Medicare databases 
from 2007 to 2015 to gather and analyze TKA cases. The purpose of this study 
was to determine whether differences in VTE incidence existed for patients 
undergoing primary TKAs depending on whether they were administered aspirin, 
warfarin, enoxaparin, or factor Xa inhibitors. 
– The authors concluded factor Xa inhibitors were associated with the lowest 
incidence of DVT and PE at 90 days. However, at two weeks and at 30 days, 
aspirin had the lowest DVT incidence. At six weeks, both aspirin and factor 
Xa inhibitors shared the lowest incidence of DVT.
• Cafri et al. (2017) evaluated the comparative safety and efficacy of aspirin, 
LMWH, factor Xa inhibitors, and vitamin K antagonists for VTE prophylaxis 
following TKA.
– The researchers concluded that a lack of evidence existed to indicate the 
superiority of any agent relative to aspirin. 
• Multiple medications are both safe and effective in the prevention of VTE 
events in patients undergoing TKA. In the past, warfarin was the most 
commonly utilized prophylactic agent, and it continues to be the agent of 
choice in patients who have previously undergone heart valve repair. 
However, due to its multiple potential drug interactions, frequent required 
laboratory monitoring of the INR, and difficulty maintaining a therapeutic 
INR, warfarin is being used far less frequently. Clinicians have begun 
favoring aspirin and factor Xa inhibitors, and both of these agents been 
endorsed by the AAOS and AACP as sole options for management of VTE 
prophylaxis in patients undergoing TKA.
• Several studies, as discussed above, have demonstrated the superiority of 
aspirin and factor Xa inhibitors over LMWH and warfarin in terms of 
efficacy of DVT prevention. Factor Xa inhibitors are costlier and 
demonstrate an increased bleeding risk compared to aspirin. Neither drug 
requires laboratory monitoring, and once daily and twice daily dosing 
options are available for both drugs. 
• After extensive review of the literature, this author’s opinion is that, in low 
risk patients undergoing TKA, aspirin is a safe and effective 
chemoprophylactic agent for DVT prevention. Aspirin has a limited risk 
profile, is cost effective and available over the counter, and does not require 
laboratory monitoring. The dosing regimen is simple and consists of one 81 
mg tablet twice daily for six weeks postoperatively. Further, in the case of 
overdose, a reversal agent is available. Clinicians must be prudent in 
analyzing each patient’s DVT risk preoperatively so as to choose the most 
superior prophylactic agent based on the patient’s history and anticipated 
period of immobilization. 
• I want to give a very special thank you to Travis Wolf, PhD, Kyle Leftwich, 
PharmD, Professor Daryl Sieg, PA-C, Professor Russell Kauffman, PA-C, 
and Dawn Hackman for all of your help in writing this scholarly project. 
Statement of the Problem
• Many potential pharmacologic options for VTE chemoprophylaxis exist, 
each with a unique profile of benefits, risks or side effects, and cost. These 
factors, along with patients’ medical history, must be considered when 
determining the most suitable option for VTE chemoprophylaxis. To date, 
no singular “gold standard” therapy is recommended for VTE prophylaxis 
following TKA.
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